Trial Profile
An open-label, multicentre, phase IV study to investigate the infliximab serum concentration of Remsima (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn's Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jun 2019
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease; Rheumatoid arthritis; Ulcerative colitis
- Focus Pharmacokinetics
- Acronyms SECURE
- Sponsors Mundipharma Pharmaceuticals BV
- 15 Jun 2019 Results (n=30) assessing efficacy of Infliximab in patients with rheumatoid arthritis, presented at the 20th Annual Congress of the European League Against Rheumatism.
- 03 Aug 2018 Status changed from recruiting to completed.
- 09 Jun 2015 New trial record